The surgical management of medullary thyroid cancer

Otolaryngologic Clinics of North America

Volumn 43, Issue 2, 2010, Pages 365-374

  Dackiw, Alan P B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA testing; Evidence based treatment; Medullary thyroid cancer; Prognosis; Surgical techniques; Thyroidectomy; Treatment guidelines

Indexed keywords

CALCITONIN; CATECHOLAMINE; PROTEIN RET;

ADRENALECTOMY; AUTOTRANSPLANTATION; CALCITONIN BLOOD LEVEL; CANCER SURVIVAL; CATECHOLAMINE BLOOD LEVEL; DISTANT METASTASIS; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LAPAROSCOPY; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; NECK DISSECTION; PARATHYROIDECTOMY; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROGNOSIS; REOPERATION; REVIEW; SURVIVAL RATE; THYMECTOMY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION;

CARCINOMA, MEDULLARY; DNA MUTATIONAL ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; LAPAROSCOPY; MULTIPLE ENDOCRINE NEOPLASIA; NECK DISSECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; REOPERATION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77953239940     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2010.01.006     Document Type: Review

References (24)

1. Saad M.F., Guido J.J., Samaan N.A. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983, 57(1):124-128.
2. Kloos R.T., Eng C., Evans D.B., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
3. Chi D.D., Moley J.F. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am 1998, 7(4):681-706.
4. Block M.A., Jackson C.E., Tashjian A.H. Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations. Arch Surg 1978, 113(4):368-372.
5. Block M.A., Jackson C.E., Greenawald K.A., et al. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 1980, 115(2):142-148.
6. Tisell L.E., Hansson G., Jansson S., et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986, 99(1):60-66.
7. Evans D.B., Fleming J.B., Lee J.E., et al. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999, 16(1):50-63.
8. Moley J.F., DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229(6):880-887. [discussion: 887-8].
9. Dralle H., Damm I., Scheumann G.F., et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994, 24(2):112-121.
10. Kebebew E., Kikuchi S., Duh Q.Y., et al. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 2000, 135(8):895-901.
11. Gimm O., Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified?. Surgery 1997, 122(6):1124-1130. [discussion: 1130-1].
12. Gimm O., Ukkat J., Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998, 22(6):562-567. [discussion: 567-8].
13. Howe J.R., Norton J.A., Wells S.A. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993, 114(6):1070-1077.
14. Gagel R.F., Tashjian A.H., Cummings T., et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988, 318(8):478-484.
15. Lee J.E., Curley S.A., Gagel R.F., et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996, 120(6):1064-1070. [discussion: 1070-1].
16. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
17. Kallinowski F., Buhr H.J., Meybier H., et al. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 1993, 114(3):491-496.
18. Dottorini M.E., Assi A., Sironi M., et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996, 77(8):1556-1565.
19. Fuchshuber P.R., Loree T.R., Hicks W.L., et al. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 1998, 5(1):81-86.
20. Schroder S., Bocker W., Baisch H., et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988, 61(4):806-816.
21. Moley J.F., Wells S.A., Dilley W.G., et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993, 114(6):1090-1095. [discussion: 1095-6].
22. Moley J.F., Dilley W.G., DeBenedetti M.K. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997, 225(6):734-740. [discussion: 740-3].
23. Fleming J.B., Lee J.E., Bouvet M., et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999, 230(5):697-707.
24. Tung W.S., Vesely T.M., Moley J.F. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995, 118(6):1024-1029. [discussion: 1029-30].